Market research
FIXX Homology Medicines Inc
Former ticker of QTTB · through Mar 25, 2024
NASDAQ USD Healthcare
Latest close
As of 12 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 224M
- P/E ratio
- 2.39
- Analyst target
- 39.6667
- Dividend yield
- Not available
- Beta
- -0.11
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 224M
- P/E ratio
- 2.39
- Analyst target
- 39.6667
- Dividend yield
- Not available
- Beta
- -0.11
About
About Homology Medicines Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Research context
Homology Medicines Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the FIXX discussion.
5 years, 7 months ago
Homology Medicines, Inc is currently in a long term downtrend where the price is trading 32.3% below its 200 day moving average.
From a valuation standpoint, the stock is 87.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 163.8.
Homology Medicines, Inc's total revenue rose by 74.1% to $980K since the same quarter in the previous year.
Its net income has dropped by 23.3% to $-30M since the same quarter in the previous year.
Finally, its free cash flow grew by 58.2% to $-13M since the same quarter in the previous year.
Based on the above factors, Homology Medicines, Inc gets an overall score of 3/5.